Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Comparison of Prostate Biopsy with or without Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: An Observational Cohort Study.

Bryant RJ, Hobbs CP, Eyre KS, Davies LC, Sullivan ME, Shields W, Sooriakumaran P, Verrill CL, Gleeson FV, MacPherson RE, Hamdy FC, Brewster SF.

J Urol. 2019 Mar;201(3):510-519. doi: 10.1016/j.juro.2018.09.049.

PMID:
30266332
2.

Does the introduction of prostate multiparametric magnetic resonance imaging into the active surveillance protocol for localized prostate cancer improve patient re-classification?

Bryant RJ, Yang B, Philippou Y, Lam K, Obiakor M, Ayers J, Chiocchia V, Gleeson F, MacPherson R, Verrill C, Sooriakumaran P, Hamdy FC, Brewster SF.

BJU Int. 2018 Nov;122(5):794-800. doi: 10.1111/bju.14248. Epub 2018 May 9.

PMID:
29645347
3.

Reducing Mortality in the Ageing Patient: Treatment of the Primary Tumour Is Not Necessary.

Lamb AD, Brewster SF, Hamdy FC.

Eur Urol Focus. 2017 Oct;3(4-5):328-329. doi: 10.1016/j.euf.2017.10.008. Epub 2017 Oct 31.

PMID:
29097093
4.

Urological recommendations from the National Institute for Health and Care Excellence (NICE) Guideline, June 2015: Suspected cancer: recognition and referral.

Jefferies ER, Brewster SF; BAUS Section on Oncology.

BJU Int. 2016 Jun;117(6):857-60. doi: 10.1111/bju.13355. Epub 2015 Nov 14. No abstract available.

5.

Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial.

Wade J, Holding PN, Bonnington S, Rooshenas L, Lane JA, Salter CE, Tilling K, Speakman MJ, Brewster SF, Evans S, Neal DE, Hamdy FC, Donovan JL; ProtecT Study Group.

BMJ Open. 2015 Sep 18;5(9):e008953. doi: 10.1136/bmjopen-2015-008953.

6.

Variation between specialist uropatholgists in reporting extraprostatic extension after radical prostatectomy.

Bryant RJ, Schmitt AJ, Roberts IS, Gill PS, Browning L, Brewster SF, Hamdy FC, Verrill C.

J Clin Pathol. 2015 Jun;68(6):465-72. doi: 10.1136/jclinpath-2014-202661. Epub 2015 Mar 19. Erratum in: J Clin Pathol. 2015 Jul;68(7):e2.

PMID:
25792751
7.

Contemporary practice and technique-related outcomes for radical prostatectomy in the UK: a report of national outcomes.

Laird A, Fowler S, Good DW, Stewart GD, Srinivasan V, Cahill D, Brewster SF, McNeill SA; British Association of Urological Surgeons (BAUS).

BJU Int. 2015 May;115(5):753-63. doi: 10.1111/bju.12866. Epub 2014 Oct 22.

8.

NICE guidelines on Prostate Cancer Active Surveillance: is UK practice leading the world?

Streeter EH, Brewster SF; BAUS Section of Oncology.

BJU Int. 2015 Jan;115(1):12-3. doi: 10.1111/bju.12752. Epub 2014 Oct 18. No abstract available.

9.

PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer.

Vickers AJ, Brewster SF.

Br J Med Surg Urol. 2012 Jul 1;5(4):162-168.

10.

Depletion of the type 1 IGF receptor delays repair of radiation-induced DNA double strand breaks.

Turney BW, Kerr M, Chitnis MM, Lodhia K, Wang Y, Riedemann J, Rochester M, Protheroe AS, Brewster SF, Macaulay VM.

Radiother Oncol. 2012 Jun;103(3):402-9. doi: 10.1016/j.radonc.2012.03.009. Epub 2012 Apr 30.

PMID:
22551565
11.

Prostate cancer: to screen or not to screen.

Bailey SJ, Brewster SF.

Arch Esp Urol. 2011 Jun;64(5):406-18. Review. English, Spanish.

PMID:
21705812
12.

Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression.

Turney BW, Turner GD, Brewster SF, Macaulay VM.

BJU Int. 2011 May;107(9):1488-99. doi: 10.1111/j.1464-410X.2010.09556.x. Epub 2010 Sep 14.

13.

Does the presence of robotic surgery affect demographics in patients choosing to undergo radical prostatectomy? A multi-center contemporary analysis.

Cheetham PJ, Lee DJ, Rose-Morris A, Brewster SF, Badani KK.

J Robot Surg. 2010 Sep;4(3):155-60. doi: 10.1007/s11701-010-0200-4. Epub 2010 Jul 10.

PMID:
27638755
14.

Low-risk localized prostate cancer: are we ready to tell patients that active surveillance is the preferred option?

Brewster SF.

BJU Int. 2008 Sep;102(8):923-6. doi: 10.1111/j.1464-410X.2008.07848.x. Epub 2008 Jul 21. No abstract available.

15.

Mutations in the AXIN1 gene in advanced prostate cancer.

Yardy GW, Bicknell DC, Wilding JL, Bartlett S, Liu Y, Winney B, Turner GD, Brewster SF, Bodmer WF.

Eur Urol. 2009 Sep;56(3):486-94. doi: 10.1016/j.eururo.2008.05.029. Epub 2008 May 23.

PMID:
18514389
16.

THE Wnt signalling pathway is a potential therapeutic target in prostate cancer.

Yardy GW, Brewster SF.

BJU Int. 2006 Oct;98(4):719-21. No abstract available.

17.

Wnt signalling and prostate cancer.

Yardy GW, Brewster SF.

Prostate Cancer Prostatic Dis. 2005;8(2):119-26. Review.

PMID:
15809669
18.

Long-term outcomes and morbidity after I125 brachytherapy for localised prostate cancer: an early UK series.

Hellawell GO, Ho K, Halliwell M, Appleby H, Le Monnier K, Boiangiu I, Davies DR, Fellows G, Whipp E, Brewster SF.

Clin Oncol (R Coll Radiol). 2005 Feb;17(1):68-9. No abstract available.

PMID:
15714935
19.
20.

Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer.

Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM.

Cancer Gene Ther. 2005 Jan;12(1):90-100.

PMID:
15499378
21.

Genetics for urologists.

Rochester MA, Brewster SF.

BJU Int. 2004 Jul;94(2):232-7. Review. No abstract available.

22.

The use of aspirin with PC-SPES may not prevent pulmonary embolism.

Biers SM, Brewster SF.

BJU Int. 2003 Dec;92 Suppl 3:e28. No abstract available.

23.
24.

Attitudes and use of alternative therapies in UK prostate cancer patients-isn't it time we were in the know?

Cheetham PJ, Le Monnier KJ, Brewster SF.

Prostate Cancer Prostatic Dis. 2001;4(4):235-241.

25.

Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease.

Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM.

Cancer Res. 2002 May 15;62(10):2942-50.

26.

Growth factors and their receptors in prostate cancer.

Hellawell GO, Brewster SF.

BJU Int. 2002 Feb;89(3):230-40. Review. No abstract available.

27.
28.
29.

Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.

Brewster SF, Oxley JD, Trivella M, Abbott CD, Gillatt DA.

J Urol. 1999 Apr;161(4):1238-43.

PMID:
10081877
30.

Inactivation of the retinoblastoma susceptibility gene in metachronous eye and bladder tumours.

Brewster SF, Knowles M, Poller D, Gingell JC.

Br J Urol. 1998 Mar;81(3):494-5. No abstract available.

PMID:
9523678
31.

Immunohistochemical analysis of nm23 protein in transitional cell carcinoma of the bladder.

Brewster SF, Gingell JC.

Br J Urol. 1996 Aug;78(2):321-2. No abstract available.

PMID:
8813946
32.
33.

The Bristol prostate cancer pilot screening study--a 3-year follow-up.

Brewster SF, Kemple T, MacIver AG, Astley JP, Gingell JC.

Br J Urol. 1994 Nov;74(5):556-8.

PMID:
7530117
34.
35.

The acute surgical admission: is mortality predictable in the elderly?

Kennedy RH, al-Mufti RA, Brewster SF, Sherry EN, Magee TR, Irvin TT.

Ann R Coll Surg Engl. 1994 Sep;76(5):342-5.

36.

Pelvic appendicitis in young adult males masquerading as cystitis.

Brewster SF, Lovering AM, McLoughlin J.

J R Coll Surg Edinb. 1994 Apr;39(2):119-20. No abstract available.

PMID:
7520067
37.
38.

Gene therapy in urological oncology: principles, strategies and potential.

Brewster SF, Simons JW.

Eur Urol. 1994;25(3):177-82. Review. No abstract available.

PMID:
8200398
39.

Fatal anaerobic infection following transrectal biopsy of a rare prostatic tumour.

Brewster SF, Rooney N, Kabala J, Feneley RC.

Br J Urol. 1993 Dec;72(6):977-8. No abstract available.

PMID:
8306172
40.

Advanced prostate cancer: what's new in hormonal manipulation?

Brewster SF, Gillatt DA.

Br J Hosp Med. 1993 May 19-Jun 1;49(10):710-1, 714-5. Review.

PMID:
7686805
41.

Re: Transrectal ultrasound.

Brewster SF.

Br J Urol. 1992 Dec;70(6):696. No abstract available.

PMID:
1486410
42.

Tumour suppressor genes in urinary tract oncology.

Brewster SF, Gingell JC, Brown KW.

Br J Urol. 1992 Dec;70(6):585-90. Review. No abstract available.

PMID:
1336697
43.

A male pseudohermaphrodite with Noonan's syndrome.

Brewster SF, Kennedy RH, Smith PJ.

Br J Urol. 1992 Jan;69(1):96-7. No abstract available.

PMID:
1737263
44.

Intravesical foreign bodies: five-year review.

Eckford SD, Persad RA, Brewster SF, Gingell JC.

Br J Urol. 1992 Jan;69(1):41-5.

PMID:
1737252
45.

The varicose vein waiting list: results of a validation exercise.

Brewster SF, Nicholson S, Farndon JR.

Ann R Coll Surg Engl. 1991 Jul;73(4):223-6.

46.

Supplemental Content

Loading ...
Support Center